Web Results

Aventis' Clomid Defeats Claims of Inadequate Warnings Based on ...

www.shb.com/news/2016/03/aventis-clomid-defeats-claims

Mar 23, 2016 ... Plaintiff Victoria Cerveny allegedly took Clomid in September and October 1992. Shortly ... The case name is Cerveny et al v. Sanofi et al.

Amgen Inc. v. Sanofi et al - RPX Search

search.rpxcorp.com/lit/dedce-56082-amgen-v-sanofi

Amgen Inc. v. Sanofi et al. 1:14-cv-01393; Filed: 11/11/2014; Case Updated Daily ; Latest Docket Entry: 12/15/2014; PACER. Create Alert ...

Results of a Pivotal Phase II Study of Brentuximab Vedotin for ...

ascopubs.org/doi/full/10.1200/jco.2011.38.0410

V Diehl, J Franklin, M Pfreundschuh , etal: Standard and increased-dose BEACOPP ... CG Cerveny, DL Meyer , etal: cAC10-vcMMAE, an anti-CD30- monomethyl ...

New developments for antibody-drug conjugate-based therapeutic ...

www.sciencedirect.com/science/article/pii/S0952791516300085

Mar 7, 2016 ... SAR408701, Sanofi, 1, 2, Solid, CEACAM5, DM4, SPDB, Yes ..... J.L. Gross, S.B. Cook, S.A. Shah, W.A. Blattler, S.J. McKenzie, V.S. Goldmacher ... S.F. Jones, S.N. Holden, W. Yu, S. Girish, J. Tibbitts, J.H. Yi, M.X. Sliwkowski, et al. ... 15; J.A. Francisco, C.G. Cerveny, D.L. Meyer, B.J. Mixan, K. Klussman, D.F. .....

Anti-Endosialin Antibody Drug Conjugate - Molecular Cancer ...

mct.aacrjournals.org/content/early/2015/07/16/1535-7163.MCT-15-0312.full.pdf

Sanofi Oncology .... 1992 publication by Rettig et al. who reported immunoreactivity of FB5 in several ..... Scott CF, Jr., Goldmacher VS, Lambert JM, et al. ... Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-.

Current methods for the synthesis of homogeneous antibody–drug ...

www.sciencedirect.com/science/article/pii/S073497501530001X

May 14, 2015 ... Sanofi-Genzyme, Glycoengineering .... The importance of conjugation site was also described by Strop et al. ..... Barginear et al., 2012; M.F. Barginear, V. John, D.R. Budman ... Doronina et al., 2003; S.O. Doronina, B.E. Toki, M.Y. Torgov, B.A. Mendelsohn, C.G. Cerveny, D.F. Chace, R.L. DeBlanc, R.P. ...

Antibody Conjugate Therapeutics: Challenges and Potential

clincancerres.aacrjournals.org/content/17/20/6389.full.pdf

Oct 15, 2011 ... Phase I. Sanofi/ImmunoGen. huB4-SPDB-DM4 .... Jeffrey SC, Torgov MY, Andreyka JB, Boddington L, Cerveny CG,. Denny WA, et al. ... V, et al. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer ...

Treatment Strategies to Optimize Outcomes With Brentuximab Vedotin

www.targetedonc.com/publications/targeted-therapies-cancer/2015/april-2015/treatment-strategies-to-optimize-outcomes-with-brentuximab-vedotin-management-of-common-and-rare-toxicities

May 19, 2015 ... Francisco JA, Cerveny CG, Meyer DL, et al. .... Bridgewater, NJ: sanofi-aventis U.S. LLC; 2013. http://products.sanofi.us/Taxotere/taxotere.pdf.

Antibody Drug Conjugates as Cancer Therapeutics - MDPI.com

www.mdpi.com/2073-4468/2/1/113/pdf

Feb 27, 2013 ... CD19. Hz IgG1 SPDB. Maytansine DM4 Phase II NHL sanofi. BT062. CD138 ..... Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace, D.F.;. DeBlanc, R.L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B.; et al. .... Kovtun, Y.V.; Goldmacher, V.S. Cell killing by antibody-drug conjugates.

Medical Countermeasures for Radiation Exposure and Related I ...

journals.lww.com/health-physics/fulltext/2015/06000/Medical_Countermeasures_for_Radiation_Exposure_and.6.aspx

... dose rate, the quality of radiation, and the time and extent of bodily exposure (;; ). ... and either have been or are currently being developed for FDA approval (;;,). ..... 2 h after irradiation had lower efficacy than a pre-irradiation injection (i.e., 12 % vs. ..... (sargramostim) is 5–10 μg kg<sup>−1</sup> d<sup>−1</sup> sc or (200–400 μg m<sup>−2</sup> d<sup>−1</sup>) (;)...

More Info

Amgen Inc. et al v. Sanofi et al - Law360

www.law360.com

Parties, docket activity and news coverage of federal case Amgen Inc. et al v. Sanofi et al, case number 1:14-cv-01317, from Delaware Court.

Current Status: Site-Specific Antibody Drug Conjugates - NCBI

www.ncbi.nlm.nih.gov

Mar 22, 2016 ... Very recently, Zhang et al. introduced a different approach to reduce the ... In 2014, Sanofi-Genzyme published a combinatorial approach of beta-1 .... Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. ... Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al.

Safety and activity of the anti-CD79B antibody–drug conjugate ...

www.thelancet.com

Apr 26, 2015 ... Vss=volume of distribution at steady state. tmax=time to reach the maximum concentration. ..... CD19-targeted maytansinoid antibody–drug conjugate SAR3419 (Sanofi, Paris, .... 9Francisco, JA, Cerveny, CG, Meyer, DL et al.